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ABSTRACT 
Purpose: Diabetes can pose a significant disease burden for patients and is often challenging to manage in underserved patient 
populations with limited access to care. A pilot study was conducted to determine the impact of a pharmacist-run insulin titration 
service, provided via telephone, to patients of a local ambulatory care clinic with a large medically, underserved patient population.  
The pilot service was implemented in Spring 2018 at Cooper Green Mercy Health Services (CGMHS) and was provided by an affiliate 
clinical pharmacist who is also on faculty at Samford University’s McWhorter School of Pharmacy. Patients who received care within 
the CGMHS diabetes clinic were eligible for referral to the service. The service was provided via a collaborative practice agreement. The 
purpose of this study was to evaluate and compare clinical outcomes of patients who received the telepharmacy service versus the 
standard of care.  Standard of care was defined as patients whose insulin therapy was managed solely by the primary care provider or 
by a diabetes clinic provider, without clinical pharmacist involvement in the patient’s care. 
Methods: This manuscript presents the results of a retrospective chart review conducted at CGMHS of patients, ages 19 or older, with 
a documented diagnosis of type 1 or type 2 diabetes who received care during the timeframe of February 2018 through September 
2018 – the initial months of the pilot telepharmacy service.  
Results: Sixty-seven patients met criteria for inclusion in the analysis - 16 managed in the telepharmacy service, 28 in diabetes clinic, 
and 23 in primary care. Patients in the telepharmacy group achieved a mean A1c change of -1.14% compared with -0.88% in the 
diabetes clinic group and +0.21% in the primary care group (p=0.061). In the telepharmacy group, 43.75% of patients experienced at 
least a 1% reduction in A1c from baseline compared with 35.71% in the diabetes clinic group and 26.09% in primary care (p=0.51). 
Conclusion: Integration of the clinical pharmacy services for insulin titration positively affected patients’ degree of glucose control. 
Although no statistically significant reductions in A1c were observed in this study, it should be noted that pharmacist intervention was 
associated with a modestly higher percent A1c reduction from baseline vs. the standard of care. The pharmacist-run service produced 
changes in clinical outcomes that numerically exceeded those experienced by patients receiving specialty care, in the diabetes clinic, 
and within primary care.  As a result of this study, the pilot program has remained in effect and is in the initial stages of expansion of 
the consult service to eligible primary care patients. 
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INTRODUCTION 
Diabetes is the seventh leading cause of death in the United 
States; leading to over 14.2 million emergency department 
visits in 2015.1 The diagnosis of diabetes is associated with a 
significant disease burden for patients, with the requirement 
of close monitoring and often frequent medication 
adjustments.  Additionally, the condition is associated with 
several complications such as kidney damage, neuropathy, 
vision loss and cardiovascular complications when poorly 
managed. Diabetic patients often need individualized therapy, 
therefore demonstrating the key role of an interdisciplinary 
team.  
 
 
 
 
Corresponding author: Crystal Deas, PharmD, BCPS  
Assistant Professor  
Samford University, McWhorter School of Pharmacy 
Email: cdeas@samford.edu 
 
Lower socioeconomic status is associated with poor self-
management behaviors often resulting in poor glycemic 
control.2,3 Poor self-management can be due to a number of 
reasons, such as misunderstanding of how to manage 
diabetes, decreased access to care, and limited transportation. 
Previous studies have evaluated the use of telepharmacy 
services to manage diabetes in low-income populations, 
showing an increased access to care has an impact on glycemic 
control in diabetes.4 
 
Cooper Green Mercy Health Services (CGMHS) is a county-
operated, outpatient healthcare center within the 
metropolitan Birmingham area that provides ambulatory care 
services, both primary and specialty care, for residents 
through use of a subsidized care model. The center serves a 
financially disadvantaged patient population who are 
adversely impacted by resource limitations that influence 
health - such as transportation issues, food insecurity, low 
health literacy, poor medication adherence, and limited 
disease self-management skills. In February 2018, Samford 
University’s McWhorter School of Pharmacy collaborated with 
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CGMHS to implement pharmacy services within the diabetes 
clinic. The service was provided at no cost to patients and was 
developed to increase access to care for those patients who 
were unable to reliably return to clinic for in-person visits but 
required close diabetes follow-up with frequent insulin 
adjustments.  
 
A key component of the pharmacy service intervention was 
the initiation of an insulin titration service pilot, which was 
provided via telepharmacy for referred clinic patients. Given 
the pilot nature of the intervention, during the initial months 
of the service, only diabetes clinic providers served as referring 
providers for patients to receive the telepharmacy service. The 
diabetes clinic providers referred patients who had self-
identified transportation difficulties and, in the provider’s 
professional judgement, had an anticipated need for frequent 
insulin adjustments. Those patients referred to the service 
were initiated on an insulin regimen by his/her CGMHS 
diabetes clinic provider prior to receiving the telepharmacy 
intervention. Under the care of a clinical pharmacist, patients 
were provided medication education and frequent telephone 
adjustments of insulin, as clinically indicated, per an 
established protocol. The process of referral and care within 
the service is depicted in Figure 1.  
 
The purpose of this study was to review clinical outcomes of 
patients receiving the telepharmacy service versus the 
standard of care. In this study, standard of care was defined as 
patients whose insulin therapy was managed either solely by 
the patient’s primary care provider or by a diabetes clinic 
provider, without clinical pharmacist involvement in the 
patient’s care.  
 
METHODS 
Study Design 
This study was a retrospective chart review. Data was collected 
from patients with a documented outpatient encounter during 
the timeframe of February 2018 through September 2018 – 
which was the initial 8 months of the pilot intervention. 
Patients included were 19 years of age or older, had a 
documented diagnosis of type 1 or type 2 diabetes, had a 
documented prescription of insulin within the medical record 
during the study timeframe, had at least two documented 
outpatient encounters in the medical record, and a 
documented baseline and follow-up glycated hemoglobin 
(A1c). Medical charts were reviewed from eligible patients 
who received insulin management within three services: (1) 
telepharmacy; (2) diabetes clinic – managed by a provider 
other than a clinical pharmacist; and (3) primary care.  
 
Patients from the telepharmacy group were identified utilizing 
a convenience sample of those who received care during the 
pilot. Of the 23 patients referred to the telepharmacy service, 
16 returned for follow-up A1c lab monitoring within the study 
period and met inclusion criteria.  Patients within the standard 
of care groups were identified by random selection via use a 
random number generator and report from the electronic 
health record (EHR) of patients seen in either primary care or 
diabetes clinic during the study period. One-hundred eight 
patient charts were identified through randomization and 
reviewed. Fifty-one patients met inclusion criteria for this 
analysis – 28 who were managed in diabetes clinic and 23 
within primary care.   
 
The primary outcome of the study was the difference in 
percent A1c change among patients in the telepharmacy group 
compared to two defined standard of care groups. Secondary 
outcomes included percent compliance with recommended 
A1c monitoring (i.e., checked every 3 to 4 months) per ADA 
recommendations, percent of patients who obtained an 
absolute A1c value of less than 7%, and percent of patients 
experiencing at least a 1-2% A1c reduction between groups.5 
 
Statistics 
Statistical analyses were conducted using SPSS (IBM Corp. 
Released 2017. IBM SPSS Statistics for Windows, Version 25.0. 
Armonk, NY: IBM Corp).  Chi-square was utilized for analysis of 
nominal data. For cases where a cell had n < 5, the Fisher’s 
Exact test was used.  ANOVA was used to compare the means 
of the three groups, and the Independent t-test was utilized 
for sub-analysis comparison of means between two groups. An 
alpha value of p < 0.05 was considered significant. The Samford 
University Institutional Review Board approved this research. 
 
RESULTS 
A total of 67 patients met criteria for inclusion in the analysis 
(Figure 2). The majority (86.57%) of patients in the study were 
diagnosed with type 2 diabetes mellitus. Baseline 
characteristics were similar between groups and are described 
in Table 1. 
 
More active management of insulin was noted in the 
telepharmacy group with the majority of patients in this group 
(87.5%, n=14) having adjustments made to their insulin 
regimen during the study period vs. 75% (n=21) of patients 
managed in diabetes clinic and 39.1% (n=9) in the primary care 
group. The majority of patients in the telepharmacy group 
(87.5%, n=14) were prescribed both a basal and bolus insulin. 
Whereas, 71.4% (n=20) of patients from the diabetes clinic 
group and 69.6% (n=16) from the primary care group were on 
combination basal and bolus insulin during the study period.    
 
Patients in the telepharmacy group achieved a mean A1c 
change of -1.14% compared with  
-0.88% in the diabetes clinic group and +0.21% in the primary 
care group (p=0.061) (Figure 3).  Secondary outcomes were 
also compared between groups (Table 2). In the telepharmacy 
group, 43.75% of patients experienced at least a 1% reduction 
in A1c from baseline compared with 35.71% in the diabetes 
clinic group and 26.09% in primary care (p=0.51). There were 
no patients in the telepharmacy group who achieved an A1c 
reduction to below 7% in this study. However, it should be 
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noted that the mean baseline A1c of patients in the pharmacy 
group was 10.56% compared to 9.44% in both of the standard 
of care groups (diabetes clinic and primary care, respectively). 
A post-hoc analysis of change in A1c revealed that 43.48% of 
patients in the primary care group, 25% of patients in diabetes 
clinic group, and 12.5% of patients in the telepharmacy group 
experienced an increase in A1c from baseline during the study 
period.  
 
The majority of patients (68.75%) in the telepharmacy group 
had an A1c rechecked and documented quarterly, per the 
American Diabetes Association recommendations, compared 
to 53.57% managed in diabetes clinic and 17.39% in primary 
care (p=0.003).5 When the rates of A1c monitoring, per ADA 
recommendations, was compared between the telepharmacy 
vs. diabetes group and telepharmacy vs. primary care group in 
a sub-analysis, there was no significant difference noted 
(p>0.05 for both comparisons). A statistically significant 
difference was noted in the sub-analysis when compliance 
with A1c monitoring was compared between diabetes clinic 
and the primary care group (p=0.013). 
 
 
CONCLUSION 
In this study, the telepharmacy intervention resulted in a larger 
percent reduction in A1c from baseline. However, a 
statistically significant difference was not noted between 
groups. While  not a statistically significant finding, the results 
are clinically significant since the primary care group 
experienced an increase in A1c during the study period. This is 
an important observation, considering diabetes is typically 
managed by primary care providers in the United States.  
 
While this study is not the first study to compare a pharmacist-
led diabetes intervention to standard practice for diabetes 
management, it is the first to our knowledge to compare 
clinical outcomes of insulin management via telepharmacy vs. 
primary care and diabetes clinic management in a primarily 
indigent patient population. A study conducted in a rural area 
of North Carolina assessed a clinical pharmacist’s role on 
telehealth team, and noted a significant reduction in weight, 
A1c and LDL within the 12 months of the pharmacy 
intervention.6 However, when outcomes of the patients 
included in the telehealth group were compared to those 
managed in a clinic setting at an academic medical center, the 
change in % A1c from baseline was non-inferior and did not 
demonstrate statistical or clinical significance.6 A similar 
observation of lack of statistical significance was noted in our 
study. However, in our study, the observation that the 
absolute % change in A1c was numerically higher in the 
telepharmacy group vs. standard of care may suggest clinical 
significance.  A study conducted by Pitlick et al. with a patient 
population similar in size and demographics to our study also 
compared outcomes at 6 months of patients enrolled in a 
pharmacist managed insulin titration service vs. standard of 
care, defined as patients managed by a primary care provider.7 
A statistically and clinically significant reduction in A1c from 
baseline was noted at 6 months between the intervention and 
standard of care group.7 It should be noted that this study did 
not utilize telepharmacy as their primary method for insulin 
titration and there was only one defined standard of care 
group. Similarly, a study conducted at the St. Louis County 
Department of Health assessed % A1c change at 3, 6, 9, 12 and 
18 months, and study conclusion.8 Two groups were compared 
in the analysis - patients managed in the pharmacist-run 
insulin titration program and patients managed solely by their 
primary care provier.8 A statistically significant difference in 
A1c at all study time points was noted between the pharmacy 
and standard of care group.8  A study conducted by Weidman-
Evans et al. evaluated the impact of a pharmacist-led insulin 
telepharmacy service utilizing faculty pharmacists, similar to 
pharmacist resources in our service, within a family medicine 
clinic.9  The faculty followed patients by phone and made 
adjustments via a two-step process: (1) use of EHR to notify 
patients’ providers of the pharmacists’ recommended changes 
to insulin and (2) subsequent notification of patients on the 
insulin adjustments, following provider approval.9 The authors 
noted a typical 3-4 hour delay after sending EHR alerts to 
initiating follow-up contact with patients to educate on the 
insulin dose change.9 The researchers noted a decrease in A1c 
from baseline of 1.55%9, which is similar to the reduction 
noted in our study. No comparisons were made to a standard 
of care group in the Weidman-Evans study; real-time 
adjustments were not made to insulin, as in our study. Given 
the telephonic delivery of the pharmacy intervention and the 
indigent nature of our clinic’s population, which increases the 
likelihood of frequent interruptions in accessible phone 
service, providing care during one point of contact is preferred.   
 
Not only is our study is innovative in that it evaluates outcomes 
of an insulin telepharmacy service in comparison to two 
standard of care groups, it also evaluated the difference in 
adherence to ADA guideline-recommended A1c monitoring 
between groups. A significant difference between groups was 
noted in percentage of patients who received A1c monitoring 
at the recommended intervals. However, when groups were 
compared separately in a sub-analysis, there was no 
statistically significant difference noted between the 
telepharmacy group vs. primary care and telepharmacy vs. 
diabetes clinic patients but rather was noted between the 
diabetes clinic vs. primary care patients.  As reimbursement 
models have shifted to value-based care with a focus on 
clinical metrics, it is important for pharmacy services to track 
the impact of interventions on adherence to guideline 
recommendations that are associated with quality metrics.  
 
Our study has important limitations. A convenience sample 
was utilized for identification of patients in the telepharmacy 
group and thus limits generalizability of results. The sample 
size was small. A high “no show” rate was observed in patients 
evaluated for inclusion in the study, which attributed to the 
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limited sample. Additionally, the small pilot was conducted in 
a single center, which may limit external validity.  
 
The results from this study suggest that innovative ways to 
provide care for patients, such as through telepharmacy, poses 
a promising solution to patients limited transportation 
resources.6 Results could be used to support the 
implementation of a similar pharmacist-run insulin titration 
service in other ambulatory care settings. Given the study 
findings, the telepharmacy service has remained in effect at 
the clinic with plans to expand the consult service to eligible 
patients within the primary care clinic. 
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Figure 1. Telepharmacy Intervention 
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Figure 2. Patient allocation by group 
 
 
 
 
Figure 3. Percent change in A1c from baseline 
 
 
 
 
 
p=0.061 
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Table 1. Baseline patient characteristics 
 
 Pharmacy Intervention 
(N=16) 
 
n(%) 
Diabetes  
Clinic 
(N=28) 
 
n(%) 
Primary 
 Care 
(N=23) 
 
n(%) 
Gender (female) 8 (50) 14 (50) 13 (56.5) 
Average age (in years) 55.8 55.04 56.4 
Type 2 Diabetes 15 (93.75) 22 (78.6) 21 (91.3) 
Average BMI (kg/m2) 31.54 33.06 32.74 
On oral diabetic 
medication 
7 (43.75) 16 (57.14) 17 (73.91) 
Non-insulin injectable 
therapy  
1 (6.25) 2 (7.14) 0 (0) 
 
 
 
 
Table 2. Study Secondary Outcomes 
 
 
 
Pharmacy Intervention 
(N=16) 
n(%) 
 
Diabetes Clinic 
(N=28) 
n(%) 
 
Primary Care 
(N=23) 
n(%) 
 
p-value 
Patients experiencing at least a 1% A1c 
reduction from baseline during study 
period  
7 (43.75) 10 (35.71) 6 (26.09) 0.510 
 
Compliance with American Diabetes Association (ADA) Recommendations  
Routine HbA1c Testing  
 
11 (68.75) 15 (53.57) 4 (17.39) 0.003 
HbA1c reduced to general goal of less 
than 7%  
 
0 (0) 4 (14.29) 3 (13.04) 0.290 
 
 
 
  
